What is Marizyme Interest Expense?
Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Marizyme's interest expense for the
three
months ended in Mar. 2024 was $ -4.16 Mil.
Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-32.69 Mil.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Marizyme's Operating Income for the
three
months ended in Mar. 2024 was $ -1.37 Mil. Marizyme's Interest Expense for the
three
months ended in Mar. 2024 was $ -4.16 Mil.
Marizyme did not have earnings to cover the interest expense.
The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Marizyme Interest Expense Calculation
Interest Expense is the amount reported by a company or individual as an expense for borrowed money.
Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Marizyme (OTCPK:MRZM) Interest Expense Explanation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Marizyme's Interest Expense for the
three
months ended in Mar. 2024 was $-4.16 Mil. Its
Operating Income
for the
three
months ended in Mar. 2024 was $-1.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the
three
months ended in Mar. 2024 was $0.56 Mil.
Marizyme's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as
| Marizyme did not have earnings to cover the interest expense. |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The higher the ratio, the stronger the company's financial strength is.
Marizyme (Marizyme) Business Description
Traded in Other Exchanges
N/A
Address
555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
Executives
| Braeden Lichti |
10 percent owner |
650 GEORGIA ST #3200, VANCOUVER A1 V6B4P7 |
| Nilesh Umedbhai Patel |
director |
555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458 |
| Michael R Stewart |
director |
5 WALNUT GROVE DRIVE, STE 140, HORSHAM PA 19044 |
| Harrison Ross |
officer: Vice President of Finance |
555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458 |
| Georgiy Kovalyov |
officer: Chief Financial Officer |
555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458 |
| David Barthel |
director, officer: Chief Executive Officer |
555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458 |
| Bradley Richmond |
officer: Acting VP of Finance |
555 HERITAGE DRIVE, SUITE 205, JUPITER FL 33458 |
| Julie B. Kampf |
director |
14054 OLD CYPRESS BEND, PALM BEACH GARDENS FL 33410 |
| Vithalbhai D Dhaduk |
director |
FNCB BANCORP, INC., 102 E. DRINKER ST., DUNMORE PA 18512 |
| Neil J Campbell |
director, officer: Chief Executive Officer |
225 CHIMNEY CORNER LANE, SUITE 2001, JUPITER FL 33458 |
| Very Donald Leroy Jr |
officer: Executive Vice President |
4 SILVERWHITE AVENUE, LITTLE SILVER NJ 07739 |
| William Hearl |
director |
448 SALK CIRCLE, GAITHERSBERG MD 20878 |
| Bruce Harmon |
officer: Chief Financial Officer |
316 DEL PRADO BLVD. S., SUITE 204, CAPE CORAL FL 33990 |
| Catherine J. Pachuk |
officer: Chief Science Officer |
1033 N. JEAGA DR, JUPITER FL 33458 |
| Satishchandran Chandrasekhar |
officer: Chief Operating Officer |
167 CARMELA COURT, JUPITER FL 33478 |
Marizyme (Marizyme) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MRZM has been successfully added to your 